US Stock MarketDetailed Quotes

TCRX TScan Therapeutics

Watchlist

4.980
0.0000.00%

Close Oct 1 16:00 ET

263.81MMarket Cap-7661P/E (TTM)

TScan Therapeutics Stock Forum

Trytosaveabit

May 29 06:08

News

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Says FDA Granted Regenerative Medicine Advanced Therapy Designation To TSC-100 And TSC-101
Benzinga· 2 mins ago

Trytosaveabit

May 9 06:08

Watching

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Inc - on-Track to Report Initial Data From Solid Tumor Clinical Trial in 2024

Jaguar8

May 9 06:04

$TScan Therapeutics (TCRX.US)$
NEWS
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors

Jaguar8

Apr 19 09:36

$TScan Therapeutics (TCRX.US)$
NEWS
TScan Therapeutics Announces Closing of Upsized Public Offering

Trytosaveabit

Apr 16 15:25

Grrr

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Announces Launch of $125 Million Proposed Public Offering

Trytosaveabit

Apr 16 15:02

Update

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics Inc -Patients Identified Across All Six Tcr-T Cohorts in Solid Tumor Program With Dosing of First Three Expected in Early May

Trytosaveabit

Mar 6 06:14

Pretty nice!

$TScan Therapeutics (TCRX.US)$ TScan Therapeutics (NASDAQ:TCRX) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.29) by 27.59 percent. This is a 73.08 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $7.21 million which beat the analyst consensus estimate of $3.34 million by 115.90 percent. This is a 132.91 percent increase over sales of $3.10 million the same period...